Status:
COMPLETED
A Safety and Efficacy Study of NAC in Patients With TA-TMA
Lead Sponsor:
The First Affiliated Hospital of Soochow University
Conditions:
Thrombotic Microangiopathies
Hematologic Diseases
Eligibility:
All Genders
Phase:
PHASE3
Brief Summary
HSCT associated thrombotic microangiopathy(TA-TMA) is a heterogeneous, fatal disorder seen within 100 days post-transplant and presents with thrombocytopenia, hemolysis, acute renal failure, mental st...
Detailed Description
Hematopoietic stem cell transplantation (HSCT) has been commonly used as a potentially curative option in the treatment of various hematological malignancies. However, it may end up with serious compl...
Eligibility Criteria
Inclusion
- Patients be scheduled to undergo HSCT;
- Not received decitabine 6 month ago;
- Without severe organ damage;
- ECOG 0-2;
- Informed consent were obtained.
Exclusion
- Be sensitive to NAC;
- Bronchial asthma；
- Peptic ulcer；
- Severe organ damage；
- Pregnancy and breastfeeding women；
Key Trial Info
Start Date :
November 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2021
Estimated Enrollment :
170 Patients enrolled
Trial Details
Trial ID
NCT03252925
Start Date
November 1 2017
End Date
October 1 2021
Last Update
February 14 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First affiliated Hospital of SooChow University
Suzhou, Jiangsu, China, 215006